Chelsea skyrockets 147% after FDA panel backs Northera
This article was originally published in Scrip
Executive Summary
After a daylong detailed discussion on 14 January, the verdict from the FDA's Cardiovascular and Renal Drugs Advisory Committee (CRDAC) for Chelsea Therapeutics' investigational drug Northera (droxidopa) was as it was two years ago: Approve the drug.